KPMG acquiring Beacon Partners

KPMG has entered into an agreement to acquire all of the assets of healthcare consultancy Beacon Partners.

Beacon Partners has a national practice that serves clients across all healthcare provider sub-segments throughout the U.S., and is ranked 15th on Modern Healthcare's list of top healthcare consulting firms. 

This marks KPMG's ninth acquisition over the last 17 months. 

"We found the strategic rationale of this acquisition to be extremely compelling," said Liam Walsh, KOMG's U.S. advisory industry leader, healthcare & life sciences, in a release. "The Beacon Partners team has made significant inroads with hospital systems, academic medical centers, integrated delivery networks and physician groups around the country. When coupled with our recent transactions involving technology consulting firm Zanett Commercial Solutions and digital/mobile firm Cynergy Systems, this acquisition significantly enhances the end-to-end transformation platform that we are diligently building within the healthcare IT market. Additionally, we expect the resulting platform to drive additional strategic and pull-through opportunities for our performance improvement, compliance, cyber and data and analytics capabilities."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.